With varied expertise in Clinical Trials phase II, III and IV, Susan Feyerabend is the ideal contact person to Sponsors, Clinical Research Organisations and the Independant Review Board (IRB) helping to optimize the design of a study. Frequently she is appointed National Coordinating Investigator in Germany.

Susan Feyerabend, MD is appointed National Coordinating Investigator (LKP) in Germany:

  • Astellas                      Serenity 6294-CL-0101
  • Ferring                       Degarelix-FE200486 CS-35A
  • Astellas                      Preside 9785-MA-1001
  • Aquinox Pharma        AQX-1125-30
  • AstraZeneca              Profound D081DC00007
  • Astellas                      9785-CL-0123
  • Clovis Oncology         Atlas CO-338-085